Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma

Goldsmith, 2023, Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results, Nat. Med., 10.1038/s41591-023-02297-5 Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, , Weiss W.A., Nat. Rev. Dis. Primers 2016, 2, 16078. Johnsen, 2019, Neuroblastoma-A neural crest Derived Embryonal Malignancy, Front. Mol. Neurosci., 12, 9, 10.3389/fnmol.2019.00009 Qiu, 2022, Advancing therapy for neuroblastoma, Nat. Rev. Clin. Oncol., 19, 515, 10.1038/s41571-022-00643-z Trigg, 2018, ALK in neuroblastoma: Biological and therapeutic implications, Cancers, 10, 113, 10.3390/cancers10040113 Wulf, 2021, Defining pathological Activities of ALK in neuroblastoma, a neural Crest-Derived cancer, Int. J. Mol. Sci., 22, 11718, 10.3390/ijms222111718 Zafar, 2021, Molecular targeting therapies for neuroblastoma: Progress and challenges, Med. Res. Rev., 41, 961, 10.1002/med.21750 Schleiermacher, 2014, Emergence of new ALK mutations at relapse of neuroblastoma, J. Clin. Oncol., 32, 2727, 10.1200/JCO.2013.54.0674 Peng, 2022, Targeting ALK Rearrangements in NSCLC: Current state of the Art, Front. Oncol., 12 Pottier, 2020, Tyrosine kinase inhibitors in cancer: Breakthrough and challenges of targeted therapy, Cancers, 12, 731, 10.3390/cancers12030731